Amgen shares took it on the chin in August following a shift in market sentiment and the approval of Repatha. Is this dip an opportunity to buy this biotech blue chip at a discount, or a warning to keep your distance?
Amgen shares took it on the chin in August following a shift in market sentiment and the approval of Repatha. Is this dip an opportunity to buy this biotech blue chip at a discount, or a warning to keep your distance?